U.S. Markets open in 2 hrs 5 mins

BioDelivery Sciences International, Inc. (BDSI)

NasdaqCM - NasdaqCM Delayed Price. Currency in USD
Add to watchlist
2.85+0.10 (+3.64%)
At close: 4:00PM EDT
People also watch

BioDelivery Sciences International, Inc.

4131 ParkLake Avenue
Suite 225
Raleigh, NC 27612
United States

Full Time Employees99

Key Executives

Dr. Francis E. O'Donnell Jr., M.D.Exec. ChairmanN/AN/A67
Dr. Mark A. Sirgo Pharm.D.Vice Chairman, Chief Exec. Officer and Pres755.64kN/A63
Mr. Ernest Robert De Paolantonio CPA, MBAChief Financial Officer, Corp. Sec. and Treasurer457.98kN/A64
Dr. Niraj Vasisht Ph.D.Chief Technology Officer and Sr. VP of Product Devel.416.36kN/A53
Mr. Albert J. Medwar MBASr. VP of Corp. & Bus. Devel.N/AN/AN/A
Amounts are as of December 31, 2016 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


BioDelivery Sciences International, Inc., a specialty pharmaceutical company, engages in the development and commercialization of pharmaceutical products principally in the areas of pain management and addiction. The company provides its products based on its patented BioErodible MucoAdhesive (BEMA) drug delivery technology, which consists of a small, erodible polymer film for application to the buccal mucosa. It offers ONSOLIS, a fentanyl buccal soluble film to treat breakthrough pain in opioid patients with cancer; BUNAVAIL, a buprenorphine and naloxone buccal film for the treatment of opioid dependence; and BELBUCA, a buprenorphine buccal film for the treatment of chronic pain. The company also develops Buprenorphine Depot Injection, an injectable microparticle formulation of buprenorphine for the treatment of opioid dependence and chronic pain. It has a licensing and development agreement with Endo Pharmaceuticals, Inc.; Evonik Corporation; Collegium Pharmaceutical, Inc.; and Meda AB. BioDelivery Sciences International, Inc. was founded in 1997 and is headquartered in Raleigh, North Carolina.

Corporate Governance

BioDelivery Sciences International, Inc.’s ISS Governance QualityScore as of June 2, 2017 is 9. The pillar scores are Audit: 5; Board: 7; Shareholder Rights: 5; Compensation: 10.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.